Oncolys BioPharma (TSE:4588) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円2,501.00
GF Value 円363.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oncolys BioPharma FFO?

FFO (Funds from operations) only applies to REITs.

TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,501.00 is trading 588.4% above its estimated GF Value™ of 円363.33. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • FFO:
  • GF Value™: 円363.33 vs. price of 円2,501.00 (588.4% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,501.00
Price
円363.33
GF Value